165 related articles for article (PubMed ID: 24592928)
1. Hepatitis B reactivation and rituximab: a new boxed warning and considerations for solid organ transplantation.
Martin ST; Cardwell SM; Nailor MD; Gabardi S
Am J Transplant; 2014 Apr; 14(4):788-96. PubMed ID: 24592928
[TBL] [Abstract][Full Text] [Related]
2. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports.
Evens AM; Jovanovic BD; Su YC; Raisch DW; Ganger D; Belknap SM; Dai MS; Chiu BC; Fintel B; Cheng Y; Chuang SS; Lee MY; Chen TY; Lin SF; Kuo CY
Ann Oncol; 2011 May; 22(5):1170-1180. PubMed ID: 21115603
[TBL] [Abstract][Full Text] [Related]
3. Adherence to hepatitis B screening and prophylactic lamivudine for prevention of rituximab-associated hepatitis B reactivation.
Liu CY; Chandrasekar PH; Masood A; Schiffer CA
J Oncol Pharm Pract; 2013 Mar; 19(1):18-23. PubMed ID: 22635416
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B.
Huang YH; Hsiao LT; Hong YC; Chiou TJ; Yu YB; Gau JP; Liu CY; Yang MH; Tzeng CH; Lee PC; Lin HC; Lee SD
J Clin Oncol; 2013 Aug; 31(22):2765-72. PubMed ID: 23775967
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group.
Kim SJ; Hsu C; Song YQ; Tay K; Hong XN; Cao J; Kim JS; Eom HS; Lee JH; Zhu J; Chang KM; Reksodiputro AH; Tan D; Goh YT; Lee J; Intragumtornchai T; Chng WJ; Cheng AL; Lim ST; Suh C; Kwong YL; Kim WS
Eur J Cancer; 2013 Nov; 49(16):3486-96. PubMed ID: 23910494
[TBL] [Abstract][Full Text] [Related]
6. Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma.
Liu WP; Zheng W; Song YQ; Ping LY; Wang GQ; Zhu J
World J Gastroenterol; 2014 May; 20(17):5165-70. PubMed ID: 24803836
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy.
Méndez-Navarro J; Corey KE; Zheng H; Barlow LL; Jang JY; Lin W; Zhao H; Shao RX; McAfee SL; Chung RT
Liver Int; 2011 Mar; 31(3):330-9. PubMed ID: 20738779
[TBL] [Abstract][Full Text] [Related]
8. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
9. An argument for the universal prophylaxis of hepatitis B infection in patients receiving rituximab: a 7-year institutional experience of hepatitis screening.
Leung C; Tsoi E; Burns G; Sievert W
Oncologist; 2011; 16(5):579-84. PubMed ID: 21464465
[TBL] [Abstract][Full Text] [Related]
10. Is antiviral prophylaxis necessary to prevent hepatitis B virus (HBV) reactivation in patients with HBV-resolved infection receiving rituximab-containing chemotherapy?
Kusumoto S; Tanaka Y; Mizokami M; Ueda R
J Clin Oncol; 2013 Dec; 31(35):4480. PubMed ID: 24220561
[No Abstract] [Full Text] [Related]
11. A study of hepatitis B virus reactivation associated with rituximab therapy in real-world clinical practice: a single-center experience.
Oh MJ; Lee HJ
Clin Mol Hepatol; 2013 Mar; 19(1):51-9. PubMed ID: 23593610
[TBL] [Abstract][Full Text] [Related]
12. Prophylaxis against hepatitis B reactivation among patients with lymphoma receiving rituximab.
Buensalido JA; Chandrasekar PH
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):151-4. PubMed ID: 24341369
[TBL] [Abstract][Full Text] [Related]
13. A drug safety evaluation of rituximab and risk of hepatitis B.
Riedell P; Carson KR
Expert Opin Drug Saf; 2014 Jul; 13(7):977-87. PubMed ID: 24821316
[TBL] [Abstract][Full Text] [Related]
14. Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy.
Kusumoto S; Tanaka Y; Ueda R; Mizokami M
J Gastroenterol; 2011 Jan; 46(1):9-16. PubMed ID: 20924616
[TBL] [Abstract][Full Text] [Related]
15. Improving testing for hepatitis B before treatment with rituximab.
Dyson JK; Jopson L; Ng S; Lowery M; Harwood J; Waugh S; Valappil M; McPherson S
Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1172-8. PubMed ID: 27388147
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B reactivation and rituximab in the oncology practice.
Villadolid J; Laplant KD; Markham MJ; Nelson DR; George TJ
Oncologist; 2010; 15(10):1113-21. PubMed ID: 20930099
[TBL] [Abstract][Full Text] [Related]
17. High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.
Cho Y; Yu SJ; Cho EJ; Lee JH; Kim TM; Heo DS; Kim YJ; Yoon JH
J Med Virol; 2016 Jun; 88(6):1010-7. PubMed ID: 26531242
[TBL] [Abstract][Full Text] [Related]
18. Prospective analysis of hepatitis B virus reactivation in patients with diffuse large B-cell lymphoma after rituximab combination chemotherapy.
Niitsu N; Hagiwara Y; Tanae K; Kohri M; Takahashi N
J Clin Oncol; 2010 Dec; 28(34):5097-100. PubMed ID: 20837949
[TBL] [Abstract][Full Text] [Related]
19. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Kusumoto S; Arcaini L; Hong X; Jin J; Kim WS; Kwong YL; Peters MG; Tanaka Y; Zelenetz AD; Kuriki H; Fingerle-Rowson G; Nielsen T; Ueda E; Piper-Lepoutre H; Sellam G; Tobinai K
Blood; 2019 Jan; 133(2):137-146. PubMed ID: 30341058
[TBL] [Abstract][Full Text] [Related]
20. Fatal reactivation of occult hepatitis B virus infection after rituximab and chemotherapy in lymphoma: necessity of antiviral prophylaxis.
Zhang B; Wang J; Xu W; Wang L; Ni W
Onkologie; 2010; 33(10):537-9. PubMed ID: 20926902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
